Holy Stone Healthcare has established the Hyaluronan Drug Delivery (HDD) platform and has developed several novel Hyaluronic Acid conjugated drugs (HACD) based on it, including ND108E. The Taiwan Intellectual Property Office (TIPO) has recently decided to grant a Patent to HACD-ND108E, which covers ND108E for the treatment of neurodegenerative diseases.
ND108E is a drug developed by Holy Stone Healthcare for neuro-degenerative diseases. The multiple actions of ND108E include the reduction of amyloid β deposit, the aggregation of phosphor Tau protein, and the enhancement of the mitochondria activities to treat or delay the progression of Alzheimer’s disease. The in vivo animal studies have demonstrated that after ND108E treatment, the impaired animal memory and learning abilities can be restored, both plaque number and plasma level of amyloid β of diseased animals were decreased, and mitochondria functions were activated. Based on the above efficacy, ND108E was able to enhance the memory and recognition functions.
An estimated 6.2 million Americans aged 65 and older are living with Alzheimer’s dementia in 2021. By 2050, the number of people aged 65 and older with Alzheimer’s dementia is projected to reach 12.7 million. Alzheimer’s disease is the most common type of dementia, comprises up to 60% to 80% of the patients with dementia. This unknown central nerve degenerative disease is characterized by progressive impaired memory and cognition loss, accompanied by decreased daily life capability and behavioral change.